Claudia Rinciog, MSc
Claudia is a Health Economics Associate Director. Since joining Symmetron in 2013, she specialises in evidence review and economic modelling in many disease areas including bipolar disease, rheumatoid arthritis, obesity, oncology, Parkinson’s disease, cardiovascular and pulmonary disease. She has supported submissions to reimbursement authorities in Europe and North America, and developed poster presentations for international conferences and manuscripts for peer-reviewed publications. Claudia graduated summa cum laude from Lafayette College in Easton, Pennsylvania, with a double degree in Biochemistry (BSc) and Economics (BA). As part of her senior year Economics thesis, she performed a regression analysis on the impact of household HIV status on the economic well-being of households in Zambia. After graduation, Claudia pursued an MSc in International Health Policy and Health Economics at London School of Economics and Political Science (LSE). As part of her LSE dissertation, Claudia interned at Medtronic in Tolochenaz, Switzerland, where she performed an explanatory statistical analysis of aortic valve replacement hospital episodes in the NHS from 2000 to 2010.
Rinciog C, Sawyer L, Diamantopoulos A, et al. Costeffectiveness of an insertable cardiac monitor in a high-risk population in the UK. Open Heart. 2019;6:e001037.
Rinciog C, Watkins M, Chang S, Maher TM, LeReun C, Esser D, Diamantopoulos A. A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK. 2017;35(4):479-491.
Rinciog C, Diamantopoulos A, Gentilini A, Bondue B, Dahlqvist C, Froidure A, Wuyts WA, Soulard S. Cost-effectiveness Analysis of Nintedanib Versus Pirfenidone in Idiopathic Pulmonary Fibrosis in Belgium. PharmacoEconomics. 2020;4(3):449-458.
Sawyer L, Azorin JM, Chang S, Rinciog C, Guiraud-Diawara A, Marre C, et al. Cost-effectiveness of asenapine in the treatment of bipolar I disorder patients with mixed episodes. J Med Econ. 2014;17(7):508-19.
Rinciog C, Myrén KJ, Aldén M, Diamantopoulos A, LeReun C. An Indirect Treatment Comparison of Cabozantinib Verse Vandetanib in Progressive Medullary Thyroid Cancer (MTC). Value Health. 2014;17(7):A616-7.
Azorin JM, Sawyer L, Chang S, Rinciog C, Guiraud-Diawara A, Marre C, et al. Cost-Effectiveness of Asenapine in the Treatment of Bipolar Disorder I Patients with Mixed Episodes. Value in Health. 2013;16(7):A549.
Mylon SE, Rinciog CI, Schmidt N, Gutierrez L, Wong GC, Nguyen TH. Influence of salts and natural organic matter on the stability of bacteriophage MS2. 2010;26(2):1035-42.
Buettner KM, Rinciog CI, Mylon SE. Aggregation kinetics of cerium oxide nanoparticles in monovalent and divalent electrolytes. Colloids and Surfaces A: Physicochemical and Engineering Aspects. 2010;366(1-3):74-79.
Rinciog C, Sawyer L, Diamantopoulos A, Elkind M, Reynolds M, Tsintzos S, Ziegler PD, Quiroz M, Wolff C, Witte KK. Economic evaluation of insertable cardiac monitors to detect atrial fibrillation and subsequently moderate stroke risk in a high-risk population in the UK. ISPOR Europe 2018. Barcelona, Spain. November, 2018.
Diamantopoulos A, Rinciog C, Forsey J, Glencorse M, Rizzo E, Murphy J. Vagus nerve stimulation for treatment-resistant depression: a budget impact analysis in England. ISPOR Europe 2018. Barcelona, Spain. November, 2018.
Rinciog C, Bermingham S, Cornic L, Diamantopoulos A, Fan Y. Cost-effectiveness of nintedanib in idiopathic pulmonary fibrosis in the US. AMCP NEXUS 2018. October, 2018.
KK. Witte, MSV. Elkind, M. Reynolds, SI. Tsintzos, PD. Ziegler, ME. Quiroz, C. Wolff, C. Rinciog, L. Sawyer, A. Diamantopoulos. Economic evaluation of insertable cardiac monitors in detecting previously undiagnosed atrial fibrillation and subsequently moderating stroke risk in a high-risk population in the UK. ESC Congress. Munich, Germany, August, 2018.
Tritaki G, Souliotis K, Bouros D, Papageorgiou I, Diamantopoulos A, Rinciog C, Schmidt U. Pharmacoeconomic assessment of nintedanib for the treatment of idiopathic pulmonary fibrosis in the Greek healthcare system. ISPOR 19th Annual European Congress. Vienna, Austria. October, 2016.